JP4852211B2 - 原核生物における必須遺伝子の同定 - Google Patents

原核生物における必須遺伝子の同定 Download PDF

Info

Publication number
JP4852211B2
JP4852211B2 JP2001569338A JP2001569338A JP4852211B2 JP 4852211 B2 JP4852211 B2 JP 4852211B2 JP 2001569338 A JP2001569338 A JP 2001569338A JP 2001569338 A JP2001569338 A JP 2001569338A JP 4852211 B2 JP4852211 B2 JP 4852211B2
Authority
JP
Japan
Prior art keywords
nucleic acid
seq
polypeptide
cell
gene product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001569338A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004516805A5 (https=
JP2004516805A (ja
Inventor
ハセルベック，ロバート
エル． オールセン，カリ
ダブリュ． ザイスカインド，ジュディス
ウォール，ダニエル
ディー． トラウィック，ジョン
ジェイ． カー，グラント
ティ． ヤマモト，ロバート
スー，エイチ．ハワード
フォーシス，アール．アリン
Original Assignee
メルク アンド カンパニー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルク アンド カンパニー インコーポレイテッド filed Critical メルク アンド カンパニー インコーポレイテッド
Publication of JP2004516805A publication Critical patent/JP2004516805A/ja
Publication of JP2004516805A5 publication Critical patent/JP2004516805A5/ja
Application granted granted Critical
Publication of JP4852211B2 publication Critical patent/JP4852211B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/26—Klebsiella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2001569338A 2000-03-21 2001-03-21 原核生物における必須遺伝子の同定 Expired - Fee Related JP4852211B2 (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US19107800P 2000-03-21 2000-03-21
US60/191,078 2000-03-21
US20684800P 2000-05-23 2000-05-23
US60/206,848 2000-05-23
US20772700P 2000-05-26 2000-05-26
US60/207,727 2000-05-26
US24257800P 2000-10-23 2000-10-23
US60/242,578 2000-10-23
US25362500P 2000-11-27 2000-11-27
US60/253,625 2000-11-27
US25793100P 2000-12-22 2000-12-22
US60/257,931 2000-12-22
US26930801P 2001-02-16 2001-02-16
US60/269,308 2001-02-16
PCT/US2001/009180 WO2001070955A2 (en) 2000-03-21 2001-03-21 Identification of essential genes in prokaryotes

Publications (3)

Publication Number Publication Date
JP2004516805A JP2004516805A (ja) 2004-06-10
JP2004516805A5 JP2004516805A5 (https=) 2008-04-24
JP4852211B2 true JP4852211B2 (ja) 2012-01-11

Family

ID=27569239

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001569338A Expired - Fee Related JP4852211B2 (ja) 2000-03-21 2001-03-21 原核生物における必須遺伝子の同定

Country Status (7)

Country Link
US (1) US20020061569A1 (https=)
EP (1) EP1268774A2 (https=)
JP (1) JP4852211B2 (https=)
KR (1) KR20020097200A (https=)
AU (1) AU2001249345A1 (https=)
CA (1) CA2404260A1 (https=)
WO (1) WO2001070955A2 (https=)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0785268A1 (en) * 1996-01-19 1997-07-23 Smithkline Beecham Plc Staphylococcus aureus methionyl-tRNA synthetase
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US7101692B2 (en) * 1999-04-15 2006-09-05 The Regents Of The University Of California Identification of sortase gene
EP1233780A4 (en) * 1999-04-15 2004-09-22 Univ California IDENTIFICATION OF THE SORTASE GENE
US7125698B2 (en) * 1999-08-09 2006-10-24 Matthew Glenn Polynucleotides, materials incorporating them, and methods for using them
EP1222197A4 (en) * 1999-10-04 2004-07-21 Merck & Co Inc MRAY GEN AND THE ENZYME OF PSEUDOMONAS AERUGINOSA
US6861516B1 (en) 1999-10-04 2005-03-01 Merck & Co., Inc. MraY gene and enzyme of pseudomonas aeruginosa
US20020120408A1 (en) * 2000-09-06 2002-08-29 Kreiswirth Barry N. System and method for tracking and controlling infections
US7349808B1 (en) 2000-09-06 2008-03-25 Egenomics, Inc. System and method for tracking and controlling infections
CA2881568C (en) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
US20020107368A1 (en) * 2000-12-07 2002-08-08 Jing-Hui Tian Helicobacter proteins, gene sequences and uses thereof
WO2002053761A2 (en) 2000-12-28 2002-07-11 Wyeth Recombinant protective protein from $i(streptococcus pneumoniae)
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
AU2002307448A1 (en) * 2001-04-20 2002-11-05 President And Fellows Of Harvard College Methods and compositions for the modulation of biofilm formation
WO2003025004A2 (en) * 2001-09-18 2003-03-27 Affinium Pharmaceuticals, Inc. Purified bacterial polypeptides involved in nucleic acid processing
AU2002328225A1 (en) * 2001-09-21 2003-04-01 Affinium Pharmaceuticals, Inc. Bacterial polypeptides involved in protein processing
WO2003045985A2 (en) * 2001-11-26 2003-06-05 Affinium Pharmaceuticals, Inc. Purified polypeptides involved in carbohydrate and coenzyme metabolism
WO2003027274A2 (en) * 2001-09-25 2003-04-03 Affinium Pharmaceuticals, Inc. Purified polypeptides from pseudomonas aeruginosa
EP1930420A1 (en) * 2001-09-26 2008-06-11 Merck & Co., Inc. Isolated nucleic acid molecules encoding a bacterial uracil phosphoribosyl-transferase enzyme, cells transformed therewith and uses thereof
JP2005505276A (ja) 2001-09-26 2005-02-24 メルク　エンド　カムパニー　インコーポレーテッド 細菌ウラシル輸送体蛋白質及び細菌ウラシルホスホリボシルトランスフェラーゼ酵素をコードする単離核酸分子、前記核酸分子で形質転換した細胞とその使用
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
EP1456380B1 (en) * 2001-11-02 2012-04-18 Giuliani International Limited Smad7 inhibitors for the treatment of cns diseases
RU2229513C2 (ru) 2001-11-23 2004-05-27 Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" Способ получения l-аминокислот, штамм escherichia coli - продуцент l-аминокислоты (варианты)
WO2003045986A2 (en) * 2001-11-26 2003-06-05 Affinium Pharmaceuticals, Inc. Purified polypeptides involved in general metabolism as possible drug targets
TW200303919A (en) * 2001-12-05 2003-09-16 Hiroyuki Ohno Cytotoxic protein and the use
US20030170694A1 (en) * 2001-12-21 2003-09-11 Daniel Wall Stabilized nucleic acids in gene and drug discovery and methods of use
AU2003202378A1 (en) * 2002-02-04 2003-09-02 Affinium Pharmaceuticals, Inc. Novel purified polypeptides from staphylococcus aureus
US6946267B2 (en) * 2002-03-13 2005-09-20 Dr. Chip Biotechnology Inc. Method for detecting Staphylococcus aureus
US8691243B2 (en) 2002-04-02 2014-04-08 Ben-Gurion University Of The Negev Research And Development Authority Protein-based Streptococcus pneumoniae vaccine
US20090252756A1 (en) * 2002-04-02 2009-10-08 Yaffa Mizrachi-Nebenzahl Protein-based streptococcus pneumoniae vaccines
WO2003087353A2 (en) * 2002-04-08 2003-10-23 Affinium Pharmaceuticals, Inc. Purified polypeptides involved in membrane biogenesis
WO2003087146A2 (en) * 2002-04-08 2003-10-23 Affinium Pharmaceuticals, Inc. Purified polypeptides from s. aureus, h. pylori and e. coli involved in cellular transport and metabolism
AU2003218563A1 (en) * 2002-04-09 2003-10-27 Affinium Pharmaceuticals, Inc. Enolase polypeptides and structures
AU2003218934A1 (en) * 2002-04-17 2003-11-03 Affinium Pharmaceuticals, Inc. Purified (3r)-hydroxymyristoyl-(acyl-carrier-protein) dehydratase polypeptide from pseudomonas aeruginosa
WO2003102544A2 (en) * 2002-05-31 2003-12-11 Cognosci, Inc. Assays for measuring matrix metalloproteinase activities
AU2003229205A1 (en) * 2002-05-31 2003-12-19 Affinium Pharmaceuticals, Inc. Bacterial polypeptides involved in viability
EP1552009A4 (en) * 2002-07-17 2006-09-13 Merck & Co Inc METHOD FOR IDENTIFYING CELLULAR GROWTH INHIBITORS
WO2004013167A2 (en) * 2002-08-01 2004-02-12 Affinium Pharmaceuticals, Inc. Purified polypeptides from enterococcus faecalis
AU2003278714A1 (en) * 2002-08-20 2004-03-11 Chiron Corporation Random transposon insertion in staphylococcus aureus and use thereof to identify essential genes
US20070053924A1 (en) * 2002-08-26 2007-03-08 Herve Tettelin Conserved and specific streptococcal genomes
FR2846668B1 (fr) * 2002-11-05 2007-12-21 Univ Aix Marseille Ii Identification moleculaire des bacteries du genre streptococcus et genres apparentes
AU2003280250A1 (en) * 2002-11-05 2004-06-07 Affinium Pharmaceuticals, Inc. Crystal structures of bacterial thymidylate kinases
WO2004041854A2 (en) * 2002-11-05 2004-05-21 Affinium Pharmaceuticals, Inc. Essential novel bacterial polypeptides
WO2004081206A2 (en) * 2003-03-12 2004-09-23 Affinium Pharmaceuticals, Inc. Novel polypeptides encoded by essential bacterial genes
WO2004058812A2 (en) * 2002-12-26 2004-07-15 Affinium Pharmaceuticals, Inc. Ribose-phosphate pyrophosphokinase polypeptides and structures
AU2003287825A1 (en) * 2002-12-31 2004-07-22 Affinium Pharmaceuticals, Inc. Crystal structures of nh3-dependent nad synthetases
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
JP5642916B2 (ja) * 2003-04-17 2014-12-17 ザ スクリプス リサーチ インスティテュート 真核遺伝コードの拡張
US20050026189A1 (en) * 2003-05-29 2005-02-03 Liangsu Wang Microbial operons
ES2505695T3 (es) 2003-07-31 2014-10-10 Novartis Vaccines And Diagnostics, Inc. Composiciones inmunógenas para Streptococcus pyogenes
US8945589B2 (en) * 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
EP1670505B1 (en) * 2003-09-18 2012-11-14 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Dna promoters and anthrax vaccines
AU2004274977B2 (en) 2003-09-19 2011-06-23 Epitopix, Llc Campylobacter polypeptides and methods of use
US20050176033A1 (en) * 2003-11-10 2005-08-11 Klyachko Elena V. Mutant phosphoribosylpyrophosphate synthetase and method for producing L-histidine
WO2005108626A2 (en) * 2004-05-07 2005-11-17 Replidyne, Inc. Mutants of staphylococcal mrs and methods of use
JP2008507296A (ja) * 2004-07-26 2008-03-13 ナノスフェアー　インコーポレイテッド 混合培養物中でメチシリン耐性黄色ブドウ球菌とメチシリン感受性黄色ブドウ球菌とを区別する方法
JP2008508320A (ja) 2004-07-29 2008-03-21 カイロン コーポレイション Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのようなグラム陽性細菌に対する免疫原性組成物
US20060078952A1 (en) * 2004-09-14 2006-04-13 Carine Robichon Method for identifying antimicrobial molecules which interfere with apolipoprotein N-acyltransferase activity
US20080095792A1 (en) * 2004-09-17 2008-04-24 Anderson Annaliesa S Polypeptides For Inducing A Protective Immune Response Against Staphylococcus Aureus
US7838010B2 (en) * 2004-10-08 2010-11-23 Novartis Vaccines And Diagnostics S.R.L. Immunogenic and therapeutic compositions for Streptococcus pyogenes
DE102004055508A1 (de) 2004-11-17 2006-06-01 Basf Ag Verfahren zur Herstellung optisch aktiver Alkohole
AU2006206577B2 (en) 2005-01-21 2012-03-08 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus aureus
NZ556651A (en) 2005-01-21 2010-05-28 Epitopix Llc Yersinia spp. polypeptides and methods of use
US8007811B2 (en) 2005-02-14 2011-08-30 Epitopix, Llc Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
GB0505949D0 (en) * 2005-03-23 2005-04-27 Univ Sheffield Polypeptides
EP1871888A4 (en) * 2005-03-30 2013-08-21 Novartis Vaccines & Diagnostic HAEMOPHILUS INFLUENZAE OF TYPE B
WO2007093848A2 (en) * 2005-08-03 2007-08-23 Affinium Pharmaceuticals, Inc. Crystalline enoyl-(acyl-carrier-protein) reductase from heliobacter pylori
US8945899B2 (en) 2007-12-20 2015-02-03 Butamax Advanced Biofuels Llc Ketol-acid reductoisomerase using NADH
JP5186689B2 (ja) 2005-11-10 2013-04-17 国立大学法人広島大学 酸化ケイ素含有物質に結合するタンパク質を介したタンパク質の固定化方法および固定化剤
EP2441469A1 (en) 2006-03-14 2012-04-18 Oregon Health and Science University Methods for producing an immune response to tuberculosis
PT2054431E (pt) * 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
US20090275058A1 (en) * 2006-09-14 2009-11-05 Universitat De Girona Method for specific detection of salmonella spp.
FR2906532B1 (fr) * 2006-09-28 2008-12-12 Biomerieux Sa Nouvel oligonucleotide marque
JPWO2008044599A1 (ja) * 2006-10-06 2010-02-12 プロテウスサイエンス株式会社 炎症腸管標的活性を有するポリペプチド、およびその利用
CA2668018A1 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
EP2134849B1 (en) * 2007-04-18 2013-07-10 Butamax (TM) Advanced Biofuels LLC Fermentive production of isobutanol using highly active ketol-acid reductoisomerase enzymes
CA2684570A1 (en) 2007-04-19 2008-10-30 Molecular Detection Inc. Methods, compositions and kits for detection and analysis of antibiotic-resistant bacteria
JP2010183841A (ja) * 2007-05-29 2010-08-26 Ajinomoto Co Inc Ｌ−アミノ酸の製造法
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
JP5658564B2 (ja) 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
KR101621837B1 (ko) 2007-09-12 2016-05-17 노파르티스 아게 Ｇａｓ57 돌연변이 항원 및 ｇａｓ57 항체
AU2008337398B2 (en) * 2007-12-19 2014-04-03 Basf Plant Science Gmbh Plants with increased yield and/or increased tolerance to environmental stress (IY-BM)
EP2537857B1 (en) 2007-12-21 2017-01-18 GlaxoSmithKline Biologicals SA Mutant forms of streptolysin O
FI20075976A0 (fi) * 2007-12-31 2007-12-31 Finnzymes Oy Menetelmät ja oligonukleotidit utaretulehdusta aiheuttavien bakteerien osoittamiseksi
EP2252702B1 (en) 2008-02-08 2014-01-29 Mayo Foundation for Medical Education and Research Detection of clostridium difficile
CN102015651B (zh) 2008-03-03 2014-12-31 Irm责任有限公司 作为tlr活性调节剂的化合物和组合物
WO2010014304A1 (en) 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
KR100975956B1 (ko) * 2008-08-08 2010-08-13 주식회사 콤슨테크놀러지 살균기능을 가지는 장애인용 이동장치
US9175353B2 (en) 2008-11-14 2015-11-03 Gen-Probe Incorporated Compositions, kits and methods for detection of campylobacter nucleic acid
EP2376111A4 (en) * 2008-11-26 2013-01-09 Merck Sharp & Dohme POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS
BRPI1011856A2 (pt) * 2009-03-23 2020-11-03 Epitopix, Llc polipeptídeos e composições de imunização contendo polipeptídeos gram-positivos e métodos de uso
HUE026855T2 (en) 2009-04-03 2016-07-28 Univ Chicago Compositions and methods related to protein a (spa) variants
JP5867952B2 (ja) 2009-06-10 2016-02-24 ノバルティス アーゲー ベンゾナフチリジン含有ワクチン
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
BR112012014624A8 (pt) 2009-12-15 2017-12-26 Novartis Ag suspensão homogênea de compostos de imunopotenciação e usos dos destes
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
EP4015523A1 (en) 2010-05-05 2022-06-22 New York University Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
CA2803298C (en) 2010-07-02 2020-07-14 The University Of Chicago Compositions and methods related to protein a (spa) variants
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
JP6048932B2 (ja) * 2010-12-28 2016-12-21 国立大学法人広島大学 酸化ケイ素と窒化ケイ素とを識別するポリペプチドおよびその利用
MX347976B (es) 2011-03-24 2017-05-22 Butamax(Tm) Advanced Biofuels Llc Celulas huesped y metodos para producir isobutanol.
US9085631B2 (en) * 2011-04-08 2015-07-21 Nov Vac APS Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
GB201116767D0 (en) 2011-09-28 2011-11-09 St George S Hospital Medical School Treatment for mitrochondrial neurogastrointestinal encephalomyopathy
EP2773655A4 (en) * 2011-10-31 2015-04-22 Merck Sharp & Dohme PROTECTION BASED ON STAPHYLOCOCCUS AUREUS SA2074 PROTEIN
US9556439B2 (en) 2012-02-09 2017-01-31 Bavarian Nordic A/S Agonists and antagonists of toll-like receptor (TLR) 13
US9181568B2 (en) * 2012-04-23 2015-11-10 Exxonmobil Research And Engineering Company Cell systems and methods for improving fatty acid synthesis by expression of dehydrogenases
JP6670106B2 (ja) 2012-04-26 2020-03-18 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌コアグラーゼ抗原およびその使用方法
NZ701099A (en) 2012-05-11 2017-04-28 Butamax Advanced Biofuels Llc Ketol-acid reductoisomerase enzymes and methods of use
US9376487B2 (en) 2012-07-10 2016-06-28 Merck Sharp & Dohme Corp. Protective vaccine based on Staphylococcus aureus SA2493 protein
CA2882620A1 (en) * 2012-09-19 2014-03-27 Novartis Ag Clostridium difficile polypeptides as vaccine
WO2014052670A1 (en) 2012-09-26 2014-04-03 Butamax (Tm) Advanced Biofuels Llc Polypeptides with ketol-acid reductoisomerase activity
CA2886748A1 (en) 2012-10-17 2014-04-24 Enterome Gene signatures of inflammatory disorders that relate to the liver
BR112015018014A2 (pt) 2013-02-01 2017-07-11 Glaxosmithkline Biologicals Sa liberação intradérmica de composições imunológicas compreendendo agonistas do receptor do tipo toll
US20150031101A1 (en) * 2013-07-26 2015-01-29 Samsung Electronics Co., Ltd. Bacterial cell having enhanced succinic acid production and a method for producing the succinic acid using the same
AU2014306074B2 (en) * 2013-08-05 2018-08-30 Greenlight Biosciences, Inc. Engineered proteins with a protease cleavage site
US10100093B2 (en) 2013-12-31 2018-10-16 Epitopix Llc Polypeptides and immunizing compositions containing Burkholderia polypeptides and methods of use
US20170049848A1 (en) * 2014-05-06 2017-02-23 Virginia Commonwealth University Target for Firmicutes and Related Bacteria: The PRP Protease
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
HRP20191671T1 (hr) 2014-05-09 2019-12-13 Immatics Biotechnologies Gmbh Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml)
FR3024903A1 (fr) 2014-08-14 2016-02-19 Biomerieux Sa Procede de quantification d'au moins un groupe de microorganismes par spectrometrie de masse
TWI649331B (zh) * 2015-06-11 2019-02-01 國立中興大學 鮑氏不動桿菌（Ａｃｉｎｅｔｏｂａｃｔｅｒ ｂａｕｍａｎｎｉｉ）多胜肽抗原及其抗體以及編碼該抗原之核酸
EP3356525A4 (en) * 2015-10-02 2019-03-27 University Of Utah Research Foundation COMPOSITIONS FOR ADJUSTABLE RIBOSOMTRANSLATION SPEED AND METHOD OF USE
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
US12247242B2 (en) * 2017-04-06 2025-03-11 Seoul National University R&Db Foundation Method for quantitatively controlling plasmid copy number in antibiotic-free plasmid maintenance system
JP7362667B2 (ja) 2018-02-12 2023-10-17 イニミューン・コーポレーション Ｔｏｌｌ様受容体リガンド
WO2019169258A1 (en) * 2018-03-01 2019-09-06 The Regents Of The University Of California Methods and compositions relating to epoxide hydrolase genes
US12514914B2 (en) 2019-05-14 2026-01-06 The University Of Chicago Methods and compositions comprising Staphylococcus protein a (SpA) variants
CA3148183C (en) * 2019-08-28 2024-10-15 Inner Mongolia Eppen Biotech Co., Ltd. RECOMMENDED STRAIN BASED ON ESCHERICHIA COLI AND ITS CONSTRUCTION PROCESS AND APPLICATION
CN114929750B (zh) 2019-09-13 2024-11-22 芝加哥大学 用于治疗葡萄球菌感染的方法和组合物
AU2020368539A1 (en) 2019-10-16 2022-04-28 Massachusetts Institute Of Technology Engineered muscle targeting compositions
JP7471688B2 (ja) * 2019-12-03 2024-04-22 中國醫藥大學 オリゴペプチド、検出キット及び医薬組成物
CA3185855A1 (en) * 2020-06-05 2021-12-09 Modernatx, Inc. Bacterial strains for dna production
JP2023547677A (ja) 2020-11-04 2023-11-13 エリゴ・バイオサイエンス キューティバクテリウム・アクネス組換えファージ、その産生方法及び使用
WO2023039476A1 (en) * 2021-09-08 2023-03-16 The Broad Institute, Inc. Engineered muscle and central nervous system compositions
CN114032313B (zh) * 2021-11-18 2024-09-17 广东海洋大学 一种评估、检测和/预测耗牛的牛肉品质性状的方法
JPWO2023210800A1 (https=) * 2022-04-28 2023-11-02
EP4662323A2 (en) * 2023-02-09 2025-12-17 Kate Therapeutics, Inc. Muscle targeted capsids

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013893A1 (en) * 1997-09-16 1999-03-25 Isis Pharmaceuticals, Inc. Peptide nucleic acids having antibacterial activity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872104A (en) * 1994-12-27 1999-02-16 Oridigm Corporation Combinations and methods for reducing antimicrobial resistance
AU5442198A (en) * 1996-11-13 1998-06-03 Q.B.I. Enterprises Ltd. Gene identification method
CA2289116A1 (en) * 1997-05-06 1998-11-12 Human Genome Sciences, Inc. Enterococcus faecalis polynucleotides and polypeptides
US6610539B1 (en) * 1997-07-10 2003-08-26 Genesense Technologies, Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
US6171838B1 (en) * 1997-08-13 2001-01-09 Smithkline Beecham Corporation ratB
US20020115217A1 (en) * 1997-10-02 2002-08-22 Smithkline Beecham Corporation Whole cell assay
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
KR20010024603A (ko) * 1998-09-09 2001-03-26 밀레니엄 파머슈티컬스 인코퍼레이티드 필수 세균 유전자 및 그의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013893A1 (en) * 1997-09-16 1999-03-25 Isis Pharmaceuticals, Inc. Peptide nucleic acids having antibacterial activity

Also Published As

Publication number Publication date
WO2001070955A8 (en) 2004-04-15
KR20020097200A (ko) 2002-12-31
JP2004516805A (ja) 2004-06-10
US20020061569A1 (en) 2002-05-23
AU2001249345A1 (en) 2001-10-03
WO2001070955A3 (en) 2002-08-01
WO2001070955A2 (en) 2001-09-27
CA2404260A1 (en) 2001-09-27
EP1268774A2 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
JP4852211B2 (ja) 原核生物における必須遺伝子の同定
US20040029129A1 (en) Identification of essential genes in microorganisms
WO2002077183A2 (en) Identification of essential genes in microorganisms
Gallagher et al. c-di-GMP arms an anti-σ to control progression of multicellular differentiation in Streptomyces
Ng et al. Regulation of the pspA virulence factor and essential pcsB murein biosynthetic genes by the phosphorylated VicR (YycF) response regulator in Streptococcus pneumoniae
JP2003518386A (ja) 大腸菌の増殖に必要であることが同定された遺伝子
US6720139B1 (en) Genes identified as required for proliferation in Escherichia coli
JP2002535007A (ja) Ｅｓｃｈｅｒｉｃｈｉａｃｏｌｉの増殖に必要であると同定された遺伝子
Kemege et al. Chlamydia trachomatis protein CT 009 is a structural and functional homolog to the key morphogenesis component RodZ and interacts with division septal plane localized MreB
Buensuceso et al. The conserved tetratricopeptide repeat-containing C-terminal domain of Pseudomonas aeruginosa FimV is required for its cyclic AMP-dependent and-independent functions
Balado et al. Biosynthetic and regulatory elements involved in the production of the siderophore vanchrobactin in Vibrio anguillarum
US6589738B1 (en) Genes essential for microbial proliferation and antisense thereto
WO2007075177A2 (en) Antibiotics targeting mreb
US20050026189A1 (en) Microbial operons
US20030170694A1 (en) Stabilized nucleic acids in gene and drug discovery and methods of use
EP1178052A2 (en) Genes identified as required for proliferation in Escherichia coli
Zhou et al. Variability of the tandem repeat region of the Escherichia coli tolA gene
Markley et al. An Escherichia coli-based bioengineering strategy to study streptolysin S biosynthesis
Wang Exploring the role of PilY1 family proteins in natural transformation
JP2002541819A (ja) 新規の必須細菌遺伝子およびこれらのタンパク質
JP2004528846A (ja) 細胞増殖を阻害する化合物の標的を特定する方法
CA2445687C (en) Compositions, methods and systems for the discovery of enediyne natural products
Heath The FadR· DNA Complex
US20040132041A1 (en) Screening method for anti-microbial drug targets by genome-saturating mutagenesis (gsm)
Jo Two novel outer membrane proteins involved in intrinsic aminoglycoside resistence in Pseudomonas aeruginosa

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20050311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110411

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110506

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110830

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110927

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111024

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141028

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees